The project will be overseen by a joint steering committee of representatives from PharmaMar and Innovex.
Innovex is the sales and marketing unit of Quintiles Transnational Corp. Innovex is a leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical, biotechnology and medical device products. Innovex operates in multiple geographies and ensures that high quality sales solutions can be provided where the customer needs them -- locally, regionally and across multiple countries. For more information, visit http://www.innovex.com.
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the biotechnology and healthcare industries. With 20,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com.
PharmaMar is the world leader biopharmaceutical company of the Zeltia
Group, committed to advancing the treatment of cancer through the discovery
and development of new marine-derived medicines. PharmaMar has five novel
compounds: Yondelis(r) has received Authorization for Commercialization
from the European Commission for advanced soft tissue sarcoma, after
failure of anthracyclines and ifosfamide, or for patients who are unsuited
to receive these agents. Yondelis(r) is also in phase III for ovarian
cancer and phase II for prostate, breast and pediatric cancers. Aplidin(r),
Kahalalide F, Zalypsis(r) and PM02734 are in clinical trials. Ph
Copyright©2007 PR Newswire.
All rights reserved